2[3]HarlandJO, Unwin N, Bhopal RS, et al. Low levels of cardiovascular risk factors and coronary heart disease in a UKChinese population[J] .Epidemiol Community Health, 1997,51:642
4[5]UK Prospective Diabetes Study Group. Tight blood pressurecontrol and risk of macrovascular and microvascular complications in type 2 diabetes[J ]. UKPDS 38.BM J, 1998, 17:703
2[1]Koya D, George LK. Protein kinase C activation and the development of diabetic complications. Diabetes 1998 ;47: 859～866.
3[2]Kunisaki M, Brusell SE, Umeda F, et al. Prevention of diabetes - induced abnormal retnal beood flow by treatment with dalpha - pocopherol. Biofactors 1998; 7:55 ～ 67.
4[3]Grant MB, Caballero S, Tarnuzzer RW, et al. Matrix metalloproteinase expression in human retinal microvaseular cells. Diabetes 1998;47:1311～1317.
5[5]Okuno A, Tamemoto H, Tobe K, et al. Troglitazone increases the number of small adipocyte without the changes of white adipose tissue in obese Zucker rats. Clin Invest 1998; 101:1354～1361.
6[6]Kelly LJ, Vicario PP, Thompson GM, et al. Peroxisome proliferator activated receptors gamma and alpha mediate in vivo regulation of uncoupling protein ( UCP - 1, UCP - 2, UCP - 3 )gene expression. Endocrinology 1998; 139: 3920～ 4927.
7[8]Berger M, Muhthauser I. Diabetes care should be based on the principles of evidence - based medicine. Inter. DIabetes Monitor 1999;11:1～3.
8[1]Matthaei S, Stumvoll M, Kellerer M, et al. Pathophysiology and Pharmacological treatment of insulin resistance. Endocrine Review 2000;21:585～618.
9[2]DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long - term complications in insulin - dependent diabetes mellitus. N Eng J Med 1993 ;329:977～ 986.
10[3]UKPDS Group. Intensive blood - glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet 1998;352:837～853.
